Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Association between BMI and Survival in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Erin Jay Feliciano, Tara Cronin, Pamela Jeannette Sung, Steven Green, Elizabeth A. Griffiths, James E Thompson, Eunice S Wang

Blood (2023) 142 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2023-189070

Published: 2023

Journal Articles

Optimal Therapeutic Strategies in Relapsed/Refractory AML with Prior Exposure to Venetoclax Based Therapy

Sawyer Bawek, Prutha Patel, Katy Wang, Kristopher Attwood, Tara Cronin, Melissa Fos, Steven Green, Pamela Jeannette Sung, James E Thompson, Elizabeth A. Griffiths, Eunice S Wang, Amanda C. Przespolewski

Blood (2023) 142 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2023-190790

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Jordan Scott, Samantha Poblete, Jared Vega, Amanda C. Przespolewski, James E Thompson, Elizabeth A. Griffiths, Pamela Jeannette Sung, Steven Green, Han Yu, Michael Shenal, Eugene Przespolewski, Eunice S. Wang, Jeffrey Baron

Blood (2023) 142 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2023-181332

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience

Riya Patel, Khalid Shalaby, Charles Roche, Hassan Awada, Elizabeth A. Griffiths, James E Thompson, Steven Green, Pamela Jeannette Sung, Eunice S. Wang, Amanda C. Przespolewski

Blood (2023) 142 (Supplement 1): 5916.

https://doi.org/10.1182/blood-2023-185058

Published: 2023

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Hassan Awada, Mina Abdelmalek, Tara L. Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark G. Faber, Arya Roy, Ashish Gupta, Matthew Gravina, Sheeba Ba Aqeel, Alankrita Taneja, Pamela J. Sung, Steven D. Green, Amanda Przespolewski, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 135–136.

https://doi.org/10.1182/blood-2022-168482

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Kyle R Wiatrowski, Pragya Srivastava, Alan Hutson, Hana Golding, Surender Khurana, Lisa King, Jody Manischewitz, Molly Sheehan, Pankit Vachhani, Amanda Przespolewski, James E. Thompson, Eunice S. Wang, Michael J Nemeth, Elizabeth A. Griffiths

Blood (2022) 140 (Supplement 1): 315–316.

https://doi.org/10.1182/blood-2022-162720

Published: 2022

Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 9010–9012.

https://doi.org/10.1182/blood-2022-164707

Published: 2022

Journal Articles

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Meriem Said, Stephanie Halliwell, Claire Puff, Kristopher Attwood, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2021-151636

Published: 2021

Journal Articles

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Mahesh Swaminathan, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Wendy Walinski, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2021-152947

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Amro Elshoury, Han Yu, Wenyan Ji, James E. Thompson, Elizabeth A. Griffiths, Amanda Przespolewski, Steven Daniel Green, Pamela J. Sung, Sheeba baAqeel, Hassan Awada, Eunice S. Wang, Peter A. Kouides

Blood (2021) 138 (Supplement 1): 3637.

https://doi.org/10.1182/blood-2021-146384

Published: 2021

Journal Articles

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Kendra Sweet, Ehab L. Atallah, Jerry P. Radich, Mei-Jie Zhang, Eva Sahakian, Melanie Mediavilla-Varela, Alexis Vistocky, Michael C. Heinrich, James E. Thompson, Michael J. Mauro, Kathryn E Flynn, Arielle Baim, Javier Pinilla Ibarz

Blood (2021) 138 (Supplement 1): 2555.

https://doi.org/10.1182/blood-2021-147954

Published: 2021

Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137613

Published: 2020

Journal Articles

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Ashkan Emadi, MD, PhD, Vu H. Duong, MD, Sandrine Niyongere, MD, Wendy Walinski, Meriem Said, Stephanie Halliwell, Kemji Eke, Kristopher Attwood, PhD, Maria R. Baer, MD, Eunice S. Wang, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141736

Published: 2020

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

NARROW

Association between BMI and Survival in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Optimal Therapeutic Strategies in Relapsed/Refractory AML with Prior Exposure to Venetoclax Based Therapy

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only